Liron Bar-Peled, PhD, is the Rullo Family Endowed Chair for Cancer Research at MGH and an Associate Professor of Medicine in Biological and Biomedical Sciences at Harvard Medical School. He received his Bachelor of Science degree in Biochemistry from the University of Georgia and his PhD in Biology from the Massachusetts Institute of Technology, where he used advanced cellular and molecular techniques to uncover how nutrients are sensed. As a Damon Runyon Postdoctoral fellow at the Scripps Research Institute, he leveraged chemical proteomic technologies to understand how cancer cells respond to oxidative stress. Having started his lab at the Krantz Family Center for Cancer Research, he has made important contributions to understanding how tumors sense and respond to metabolic stress and identifies new druggable vulnerabilities by integrating technologies that leverage high-throughput biochemistry, chemistry, and analytics with clinical insights. Liron’s work led to the founding of Scorpion Therapeutics (acquired by Eli Lily) and he has been widely recognized in the field as a Pew-Stewart Scholar, Mark Foundation Emerging Leader Award, NIH/NCI Merit Award, V Foundation Scholar, MRA young investigator and Damon Runyon Innovator.